Literature DB >> 20471999

The maternal immune activation (MIA) model of schizophrenia produces pre-pulse inhibition (PPI) deficits in both juvenile and adult rats but these effects are not associated with maternal weight loss.

Amy R Wolff1, David K Bilkey.   

Abstract

The developmental onset of deficits in sensorimotor-gating was examined in the maternal immune activation (MIA) animal model of schizophrenia. Pre-pulse inhibition (PPI) deficits were evident in juvenile MIA rats. This parallels the sensorimotor-gating deficits observed in groups at high-risk of schizophrenia. PPI deficits were independent of maternal weight loss following the MIA manipulation, suggesting that this measure may not be a useful marker of treatment efficacy. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20471999     DOI： 10.1016/j.bbr.2010.05.008

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN： 0166-4328            Impact factor:   3.332


  27 in total

1.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

Review 2.  Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia.

Authors:  Anna M Fineberg; Lauren M Ellman
Journal:  Biol Psychiatry       Date:  2013-02-12       Impact factor: 13.382

3.  Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC.

Authors:  Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams
Journal:  Synapse       Date:  2012-05-15       Impact factor: 2.562

4.  Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy.

Authors:  J G Howland; B N Cazakoff; Y Zhang
Journal:  Neuroscience       Date:  2011-11-11       Impact factor: 3.590

5.  Prenatal immune challenge in rats: effects of polyinosinic-polycytidylic acid on spatial learning, prepulse inhibition, conditioned fear, and responses to MK-801 and amphetamine.

Authors:  Charles V Vorhees; Devon L Graham; Amanda A Braun; Tori L Schaefer; Matthew R Skelton; Neil M Richtand; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2014-11-08       Impact factor: 3.763

6.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

7.  Prenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats.

Authors:  Ying Zhang; Brittany N Cazakoff; Chester A Thai; John G Howland
Journal:  Neuropharmacology       Date:  2011-03-02       Impact factor: 5.250

8.  Behavioral alterations in rat offspring following maternal immune activation and ELR-CXC chemokine receptor antagonism during pregnancy: implications for neurodevelopmental psychiatric disorders.

Authors:  Stephanie A Ballendine; Quentin Greba; Wojciech Dawicki; Xiaobei Zhang; John R Gordon; John G Howland
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-12       Impact factor: 5.067

9.  Individual differences in maternal response to immune challenge predict offspring behavior: contribution of environmental factors.

Authors:  Stefanie L Bronson; Rebecca Ahlbrand; Paul S Horn; Joseph R Kern; Neil M Richtand
Journal:  Behav Brain Res       Date:  2011-01-19       Impact factor: 3.332

Review 10.  Placental programming of neuropsychiatric disease.

Authors:  Panagiotis Kratimenos; Anna A Penn
Journal:  Pediatr Res       Date:  2019-04-19       Impact factor: 3.756
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.